In the previous reports the prevalence of GADAb in healthy population has been reported to be 0.5–0.8% [9, 10], which is lower than that in non-insulin treated type 2 diabetes (T2D) (2–6%) and that in T2D who develop insulin dependency (11–15%) [11–15], supporting that GADAb is associated with the development of diabetes and insulin dependency. The gene discussed is INS; the disease is type 2 diabetes mellitus.